Connect with us

Micro Caps

Gentech Holdings Inc (OTCMKTS: GTEH) Heats Up as Brand Incubator Launches its Beverage FIZZIQUE™ & Reports Record Revenues

Published

on

Gentech Holdings Inc (OTCMKTS: GTEH) has been heating up in recent trading and nudging northbound on a surge of trading volume. The stock has quickly attracted a significant shareholder base including some big players in small caps who are heavily accumulating at current levels. The stock has a history of explosive moves running from current levels to highs of $0.0189 per share starting around this time last year. Speculators are looking for a break over $0.019 for confirmation of the next leg up. To more accurately reflect its business, the Company recently applied to FINRA for approval on a Change of Corporation Name to Supplement Group (USA), Inc.  

GTEH owns a number of brands that are experiencing rapid growth including Fizzique in the booming beverage space and penny stock speculators are all too aware of the explosive history of penny stock beverage stocks. The Company has seen explosive revenue growth recently reporting “for the calendar year (2021), the business expects a full calendar year revenue figure to top $1.35m, exceeding expectations and 400% up on 2020’s $250k revenue year. David Lovatt, CEO of GenTech Holdings, recently stated: “We conservatively estimate it alone can bring in over $3.5 million in topline revenues next year, taking us to well over $7 million in 2022, but my feeling is that Fizzique will do significantly more than that, as will the other brands, giving me the firm belief that we should be looking at $10m for 2022. Management continues to work hard behind the scenes recently cutting the authorized shares to 33bn signaling an end to significant further dilution as management lays out a plan to further reduce the authorized share capital. They also announced a share buyback program and enacted a no reverse split policy. According to their last filing the Company has $4.175 million in the treasury and is well funded moving forward. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gentech Holdings Inc (OTCMKTS: GTEH) operating out of Wheat Ridge, Colorado, owns and operates leading functional foods brand, SINFIT Nutrition, which offers a range of high-end Functional Foods as well as American Metabolix, Inc. which provides a diverse range of Nutritional Supplements through its brands American Metabolix, Storm Lifestyles and Core Natural Sciences. The Company owns the following brands; Yourganics, American Metabolix, Core Natural Sciences, SWFT, Nature Soothie, Storm Lifestyles, Secret javas, SINFIT, MPB Snacks, Fizzeque, and NXT Bar. 

Gentech is led by CEO Leonard K. Armenta Jr., a seasoned executive who spent the last 15+ years in sales, marketing and corporate management as well as consulting both public and private companies. He has helped build, work and consulted for several well-known public companies including; MusclePharm, a Top Sports Nutrition and beverage company, with revenues over $100mm and Creative Edge Nutrition a Sports Nutrition and formally a MMJ company. He is appearing on MoneyTV this week to walk shareholders through the process that Fizzique has been going through and is now starting to get results and what the future holds for the brand now that it has distributors, retailers, orders and inventory. 

GETH has seen explosive revenue growth recently reporting “for the calendar year (2021), the business expects a full calendar year revenue figure to top $1.35m, exceeding expectations and 400% up on 2020’s $250k revenue year. David Lovatt, CEO of GenTech Holdings, recently commented “Once Fizzique sales start to hit, we conservatively estimate it alone can bring in over $3.5 million in topline revenues next year, taking us to well over $7 million in 2022,” added Lovatt. “But my feeling is that Fizzique will do significantly more than that, as will the other brands, giving me the firm belief that we should be looking at $10m for 2022. And we haven’t even started talking about the STORM set of products yet.” 

The Company recently reported one of its fledgling brands “Nature Soothie” who has sold out each production run to Sprouts and Whole Foods to date has shown 600% growth in Q4 2021 when compared with Q4 2020 unit sales. Nature Soothie™ suckers sold around 90,000 individual units between Oct 1 2021 and Dec 31st 2021, showing an approximate 600% growth over the 13,000 individual units sold between Oct 1 2021 and Dec 31st 2021. The brand is quickly being picked up by many major supermarkets and independent chain stores across the country including as Giant Eagle, Wegmans, Raley’s, Safeway, Vitacost and Harmony’s to name a few. 

To get an inside look at GTEH Subscribe to Microcapdaily.com immediately by entering your Email below

GTEH

The American Metabolix, Inc., acquisition was a September 1st closing and accounted for c.$300k in its first three full months of operations at GenTech, translating to at least a $1.2m revenue brand on its own in the future. 

Gentech Holdings also recently reported the first retail orders for its carbonated protein drink IZZIQUE™ during the opening two weeks of 2022 from UNFI, North America’s largest publicly traded wholesale distributor of health and specialty foods, for its brand Fizzique™ Fizzique was also accepted and setup was completed on the VitaCost / Kroger Digital platform. Management recently commented Fizzique could take the Company to over $7 millioin in revenues in 2022. And they haven’t even started talking about the STORM set of products yet.” 

Fizzique recently announced that it has signed Megan Olivi  as brand ambassador. Mrs. Olivi serves as a host and lead reporter for the UFC™ on ESPN™ as well as commenting on NFL™ for Fox™. During the fight broadcasts, Megan can be seen live reporting through the night, conducting interviews, and hosting from the desk. She also serves as a sideline and feature reporter during football season for NFL on Fox. Mrs. Olivi gets 1.25 million views on the UFC prelim fight and almost 2 million on the UFC pay per views per fight. As well as over 1m followers on various social media platforms and achieves exceptional engagement across all channels which are all essential metrics when choosing a Brand Ambassador. 

Inventory for Fizzique will start to arrive before the end of January with the full 2m initial order for product expected to be complete before mid-February. A further 2m cans have been reserve orders pending the value of initial orders for the product and expect to be on-hand towards the middle of the year at the latest. 

For More on GTEH Subscribe Right Now!

GTEH has been heating up in recent trading and nudging northbound on a surge of trading volume. The stock has quickly attracted a significant shareholder base including some big players in small caps who are heavily accumulating at current levels. The stock has a history of explosive moves running from current levels to highs of $0.0189 per share starting around this time last year. Speculators are looking for a break over $0.019 for confirmation of the next leg up. To more accurately reflect its business, the Company recently applied to FINRA for approval on a Change of Corporation Name to Supplement Group (USA), Inc. GTEH owns a number of brands that are experiencing rapid growth including Fizzique in the booming beverage space and penny stock speculators are all too aware of the explosive history of penny stock beverage stocks. The Company has seen explosive revenue growth recently reporting “for the calendar year (2021), the business expects a full calendar year revenue figure to top $1.35m, exceeding expectations and 400% up on 2020’s $250k revenue year. David Lovatt, CEO of GenTech Holdings, recently stated: “We conservatively estimate it alone can bring in over $3.5 million in topline revenues next year, taking us to well over $7 million in 2022, but my feeling is that Fizzique will do significantly more than that, as will the other brands, giving me the firm belief that we should be looking at $10m for 2022. Management continues to work hard behind the scenes recently cutting the authorized shares to 33bn signaling an end to significant further dilution as management lays out a plan to further reduce the authorized share capital. They also announced a share buyback program and enacted a no reverse split policy. According to their last filing the Company has $4.175 million in the treasury and is well funded moving forward. We will be updating on GTEH when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with GTEH.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in GTEH either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Cosmos Holdings Inc (NASDAQ: COSM) Huge Short Position Panicks as COSM Rockets Up the Charts

Published

on

Cosmos Holdings Inc (NASDAQ: COSM) is rocketing up the charts northbound since reversing off $0.0675 lows earlier this month where we first gave the heads up on COSM at around a dime in our article here. Since than COSM has rocketed northbound recently surpassing $0.60 per share with speculators pointing at $1 as the next stop. In our previous article on COSM on November 13 when COSM was $0.10 we stated: “COSM was trading well over $3 at the beginning of this year but has been heavily shorted since than with current estimates of well over 5 million shares sold short and almost the entire public float sold short. 

While COSM has been heavily shorted into oblivion, the Company is actually doing quite well recently reporting revenues for the 3 months ended September 30 were $12 million. The Company is successfully developing their business recently closing a deal with Iberica, a European Airline, for in flight distribution of their products. The CEO has bought millions of shares at current levels and COSM is beginning to go viral on social media trending on the sub reddit Short Squeeze, Number #1 on Stocktwits and multiple videos being made on YouTube about a massive short squeeze taking place in small caps. 

COSM Friday December 2, 4PM Close Update: COSM had a wild trading day on Friday dropping to $0.42 in the morning before rocketing up to $0.61 highs. This was followed by another drop to the $0.47 range before COSM rocketed up in late afternoon trading, closing at $0.53 on 205 million shares traded. COSM was up 33% on the day on around $110 million in dollar volume. COSM is setup for an enormous week ahead, looking to overtake the $0.845 from Monday and embark on a blue-sky breakout with $1 as the first stop. We gave the heads up on COSM when the stock was below $0.10 per share at the beginning of November. We will be updating on COSM as soon as anything new happens so make sure you are subscribed to Microcapdaily by entering your email in the box below.  

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

No alternative text description for this imageCosmos Holdings Inc (NASDAQ: COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. 

The Number #2 post on the subreddit ShortSqueeze currently is titled: COSM about to test resistance. A pump through $0.66 and lift off to over $1.00 is possible now. 

In another post on COSM in the subreddit ShortSqueeze rubio2430 states: “$COSM you cant make this stuff up. this baby is ready for space. the shorts are burying themselves on the daily. constant pr’s, growing fundamentals, no plans on dilutions, dual listing on upstream soon—the list goes on! 

nimble_broccoli replied: Why this is a good play: 

1.) Extremely tiny Marketcap 2.) CEO buying 15’000’000 shares 3.) Good fundamentals, unlike other plays, they actually sell products valued around 10x the valuation. Q1/22 was profitable. 4.) Getting momentum on social media (Reddit Twitter, YT) 

Next catalysts: -Info that they will not be delisted from NASDAQ -Degen and Retail FOMO kicking in -Shorts starting to cover their asses 

In addition, consider this: The stock was somewhere between USD 2 and USD 12 the past ~8 years. Most Hodlers bought back then, do you think they will sell now? Do your own thinking but if one of my stocks dropped 80+ % i d not sell, i d just hope for a miracle or ride it out. Thus, not many regular buy&hold holders of the stock are expected to sell. 

Cosmos operates in the business of full-line pharmaceutical wholesale distribution and serves approximately 1,500 independent retail pharmacies and 40 pharmaceutical wholesalers in Greece region by providing brand-name and generic pharmaceuticals, over-the-counter medicines, vitamins and nutraceuticals. Cosmos invests in technology to enhance safety, distribution and warehousing efficiency and reliability. Specifically, the Company operates a fully automated warehouse system with three robotic systems, two ROWA™ types and one A-frame type, that ensure 0% error selection rate, accelerate order fulfillment, and yield higher cost-efficiency in our distribution center. Cosmos has 3 operating subsidiaries including:

SkyPharm
Sky Pharm SA is headquartered in Thessaloniki, Greece. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. We buy from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers, and export to European markets where demand and prices are substantially higher.
.
DHN
Decahedron Ltd. is a pharmaceutical wholesaler incorporated in the UK in August 2011. It is audited by the MHRA under European GDP (Good Distribution Practices). They are also a full member of the EAEPC and have been audited by TÜV on their behalf.
.
Cosmofarm
Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. The company is approved and authorized by the National Organization for Medicines under Good Distribution Practices to distribute a comprehensive range of pharmaceutical products. Cosmofarm’s core activity is sourcing, procuring, and distributing branded.
.
To Find out the inside Scoop on COSM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

COSM

Image

COSM business is strong and Q3 highlights include closing a $7.5M capital raise via public offering and signing an exclusive agreement to market and distribute Nickelodeon’s SpongeBob and PAW Patrol kids’ vitamins in Greece and Cyprus, aiming to reach out 11,000 pharmacies and 120 wholesalers in Greece and 780 pharmacies in Cyprus. They also executed a letter of intent for a strategic co-venture agreement with Smart for Life (SMLF) to cross market products and services in their reciprocal markets. COSM also entered into an LOI to acquire ZipDoctor Inc., and entered into an agreement with Virax Biolabs (VRAX), to become the distributor of Monkeypox Virus Real-Time PCR Detection Kits, having the exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the test kits across Europe on a non-exclusive basis. SkyPharm officially launched its first Sky Premium Life products on Amazon in the United States. Cosmos targets having all 85 SKUs listed on Amazon by year end. COSM entered into an LOI to acquire Pharmaceutical Laboratories CANA S.A., and another LOI to acquire LIFE NLB, Ltd.’s product portfolio, including Bone-Vio® and Bone-X, related to bone health targeting the human gastrointestinal microbiome. 

Last week COSM announced its Sky Premium Life luxury food supplement brand will be sold on Ronda, the official inflight magazine of the airline company Iberia of BRITISH AIRWAYS group. Ronda is available free of charge to the over 10 million passengers who fly Iberian Airlines annually. Iberia Airlines, majority owned by British Airways, has a fleet of 147 aircrafts and engages in over 600 daily flights. 

https://twitter.com/nxtplse/status/1597365583934545920

For More on COSM Subscribe Right Now!

Currently trading at a $36 million market valuation COSM os is 92,008,281 the Company recently reported Q3 Revenues of $12 million down a bit from the same time last year due to a high variation in FX differences between EUR and GBP to USD. COSM was trading over $4 this time last year however OS has increased substantially since then.  COSM is an exciting opportunity in small caps; the stock was shorted into oblivion and currently there are minimum 5.8 million shares short and was way oversold to pennies and it looked as if it would definitely get delisted by the Nasdaq however, led by able CEO Grigorios Siokas, Cosmos is fighting back. Mr. Siokas continues to buy more COSM at current price levels, putting his money where his mouth is as COSM rockets towards $1 which is now just a day and half away if the stock continues up at the same trend.  We will be updating on COSM when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in COSM either long or short and we have not been compensated for this article.

Continue Reading

BioPharma

Cosmos Holdings Inc (NASDAQ: COSM) Heating Up as Co Looks to Take on Massive 5 million Share Short Position

Published

on

Cosmos Holdings Inc (NASDAQ: COSM) is making a rapid move up the charts since recent reversing off $0.0675 lows. The stock was trading well over $3 at the beginning of this year but has been heavily shorted since than with current estimates of well over 5 million shares sold short and almost the entire public float sold short. COSM is quickly emerging as the latest short squeeze at the top of speculators watch lists and is currently trending on stocktwits and the sub reddit ShortSqueeze on Reddit. 

The Company is fighting back against the shorts and planning a lawsuit and CEO Grigorios Siokas recently put his money where his mouth is when he bought 12,500,000 shares of the stock at $0.12 average for about $1.5 million. While in danger of being delisted from the Nasdaq if they don’t get the stock price back over $1 by the end of November the Company is doing well recently reporting its first ever net income on $13,208,504 in revenues for the 3 months ended June 30, 2022. Cosmos is also acquiring ZipDoctor Inc. from American International Holdings Corp (AMIH) 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Cosmos Holdings Inc (NASDAQ: COSM) is an international healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. On August 2, 2022, the Company filed a Fictitious Firm Name Certificate in Nevada to do business under the name Cosmos Health, Inc. and will seek shareholder approval at its annual shareholders meeting scheduled for December 2, 2022 to amend its Articles of Incorporation for the name change. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and over-the-counter (“OTC”) medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors.  

Cosmos operates in the business of full-line pharmaceutical wholesale distribution and serves approximately 1,500 independent retail pharmacies and 40 pharmaceutical wholesalers in Greece region by providing brand-name and generic pharmaceuticals, over-the-counter medicines, vitamins and nutraceuticals. Cosmos invests in technology to enhance safety, distribution and warehousing efficiency and reliability. Specifically, the Company operates a fully automated warehouse system with three robotic systems, two ROWA™ types and one A-frame type, that ensure 0% error selection rate, accelerate order fulfillment, and yield higher cost-efficiency in our distribution center. Cosmos has 3 operating subsidiaries including:

SkyPharm
Sky Pharm SA is headquartered in Thessaloniki, Greece. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. We buy from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers, and export to European markets where demand and prices are substantially higher. The …
DHN
Decahedron Ltd. is a pharmaceutical wholesaler incorporated in the UK in August 2011. It is audited by the MHRA under European GDP (Good Distribution Practices). They are also a full member of the EAEPC and have been audited by TÜV on their behalf. They import and export branded, generic and …
Cosmofarm
Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. The company is approved and authorized by the National Organization for Medicines under Good Distribution Practices to distribute a comprehensive range of pharmaceutical products. Cosmofarm’s core activity is sourcing, procuring, and distributing branded

https://twitter.com/ChairmanOtc/status/1590877348752420866

To Find out the inside Scoop on COSM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

COSM

ImageOn August 22 Cosmos provided a business update and reported financial results for the second quarter and six months ended June 30, 2022. Revenues were $13,208,504 for the 3 months ended June 30, 2022 compared to $14.8 million for the same period last year. 

Greg Siokas, Chief Executive Officer of Cosmos Health, stated, “We increased our profitability for the first half of 2022 due to the increase of gross profit margin to 14.2% from 11.5% for the respective period of 2021. This increase is attributed mainly to the organic growth of our proprietary nutraceutical brand, Sky Premium Life® (“SPL”). We achieved positive income from operations of $0.2 million for the first half of 2022 compared to a loss of $3.1 million in the same period last year and positive EBITDA of $0.8 million for the first half of 2022 compared to a loss of $2.8 million for the same period last year. Gross profit increased by 23.0% to $3.7 million for the six months ended June 30, 2022. We continue to carefully manage expenses and reduced operating expenses by nearly 43.7% and 41.9% for the three and six months ended June 30, 2022, respectively. During the quarter, we launched a new premium line of nutritional supplements, Mediterranation. The Mediterranation line uses organic herbs and plant extracts such as crataegus, hibiscus, dittany of Crete, oregano, mastic and kritamos, found in specific regions in Greece and the Mediterranean. These unique formulations contain a proprietary blend of vitamins and minerals and are made with the highest quality raw materials. There is high demand among consumers for supplements that utilize high quality Mediterranean ingredients, such as polyphenols, which possess antioxidant and anti-inflammatory properties. We expect the launch of the Mediterranation line will further enhance our growth strategy and we look forward to expanding the product line into new global markets through our growing distribution channels. We also launched our SPL products on Amazon Singapore and are in the process of launching on Amazon United States and Amazon Canada in the third quarter of 2022. These new markets provide an untapped growth opportunities and new audiences for our proprietary SPL brand. Our goal is to grow our portfolio of branded nutraceuticals and reach up to 150 SKUs by the end of 2022.” 

Earlier this year Cosmos announced an LOI to acquire ZipDoctor Inc. from American International Holdings Corp (AMIH). AMIH will continue to manage all aspects of the day-to-day operations of ZipDoctor including product development, marketing, and operational support. ZipDoctor Inc., is a direct-to-consumer subscription-based telemedicine platform, that expects to provide its customers affordable, unlimited, 24/7 access to board certified physicians and licensed mental and behavioral health counselors and therapists. ZipDoctor’s online telemedicine platform will be available to customers across the United States and offers English and Spanish coverage with virtual visits taking place either via the phone or through a secured video chat platform. 

On October 17, 2022, Cosmos entered into a Securities Purchase Agreement with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a public offering, an aggregate of $7,500,000 of securities, consisting of (i) 62,500,000 shares of Common Stock, (ii) pre-funded Warrant in lieu of shares of Common Stock, and (iii) warrants to purchase 125,000,000 shares of Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”).  Under the terms of the Purchase Agreement, the Company agreed to sell one share of its Common Stock or a Pre-Funded Warrant and two Common Warrants for each share of Common Stock or Pre-Funded Warrant sold at a unit price of $0.12.  For each of 15,662,603 Pre-Funded Warrant sold in the Offering, the number of shares of Common Stock offered were decreased on a one-for-one basis. 

https://twitter.com/AirGoodman24/status/1591938222548189186

 For More on COSM Subscribe Right Now!

Currently trading at a $10 million market valuation COSM is the latest potential short squeeze at the top of speculators watch lists. With $35 million in current liabilities and an inability to collect on accounts receivables that currently stand at over $25 million COSM stock has lagged even as the Company reports its first ever net income on $13,208,504 in revenues for the 3 months ended June 30, 2022. The short position on COSM has grown to well over 5 million shares short and currently the entire public float is sold short. Now that the cat is out of the bag and the stock is surging northbound COSM short squeeze should be at the top of small cap speculators watch lists. We will be updating on COSM when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in COSM either long or short and we have not been compensated for this article.

Continue Reading

BioPharma

Plandai Biotechnology Inc (OTCMKTS: PLPL) Breaking Out Northbound after Closing on the “Smart Hotel” EV Hotel Corp Reverse Merger

Published

on

Plandai Biotechnology Inc (OTCMKTS: PLPL) is breaking out northbound up over 30% on $300,000 in dollar volume in the first 2 hours of trading on Thursday. The move comes as the incoming CEO of with EV Hotel Corp., announced the Company closed on the acquisition of 100% stock of EV Hotel Corp., with the official announcement coming next Tuesday. Plandai also plans to file with the SEC, Finra and OTC Markets Group for both a formal name and symbol change to reflect the new direction and identity of the Company. 

EV Hotel™ has developed the world’s first proprietary disruptive hospitality platform – the “smart hotel,” combining technology, automation, IoT, and crypto with best-in-class service, stylish design, and upscale amenities to deliver a more efficient hotel operation, happier guests, and more streams of revenue. EV Hotel™ CEO Ken Patel states: “I came to set the ultimate goal to revolutionize the hospitality industry like never before. Now one item is checked off and many more to achieve.” 


Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Plandai Biotechnology Inc (OTCMKTS: PLPL) is a perfect reverse merger candidate with just $420,000 in total liabilities and no note payables or convertible debt on the books having previously massively diluted the stock. Reverse merger SPACS can be more explosive than biotech’s when the incoming Company has real value but is undiscovered to investors and many RM stocks, we have covered on this website have gone from pennies to dollars. Two recent RM runners that stand out are TSNP/HMBL which went from sub pennies (where we first wrote about it) to several dollars per share. The other is HRBR which went from a few cents (where we first wrote about it) to $3 plus.

The incoming Company: EV Hotel™ developed the world’s first proprietary disruptive hospitality platform – the “smart hotel,” combining technology, automation, IoT, crypto and NFT with best-in-class service, stylish design, and upscale amenities to deliver a more efficient hotel operation, happier guests, and more streams of revenue. EV Hotel™ revolutionizes how hotels operate by streamlining the guest experience, with thoughtful technologies that eliminate frustrating chokepoints across the guest journey, reimagining the hotel front desk with streamlined check in from its proprietary EV Smart™ app, automating hotel operations, providing upscale amenities, and building new revenue streams which provides a central control point over the guest experience including room controls, concierge, room service and more. The EV Smart™ app provides an all-in-one solution that provides for a seamless guest experience. 

Image

To Find out the inside Scoop on PLPL Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

PLPL

EV Hotel’s™ “IoT Smart Rooms” incorporates technologies allowing guests to relay requests directly into hotel service allowing hotel staff to see and respond in real-time, based on device-specific data, automatically providing alerts about problems reducing guest disruptions and out-of-service rooms and eliminating the need for preventative maintenance, saving both labor and equipment costs, all while providing significant energy savings. 

EV Hotel™ operates a franchise model and it’s first franchisee is obtaining permits and converting a 63-year-old 114 room Travelodge into Phoenix, Arizona’s first ever smart hotel. It will be a new, cutting-edge hotel in a historically designated building. The design preserves the historic building and transforms it into the city’s first fully automated smart hotel with a hip pool that will mirror a trendy Miami style vibe. 

EV Hotel™ also feature NFT (non-fungible token) artwork that is available for purchase in the hotel’s NFT Lobby and in its designer rooms, featuring one-of-a-kind NFT pieces for sale. Each guest owns their rewards via an NFT purchase, which allows them to sell their entire membership – with its rewards intact – to other travelers. EV Hotel™ is the first hospitality brand with integrated cryptocurrencies, with a dedicated Crypto experience center and trading floor backed by CDX and a special Crypto ballroom.The Parties are conducting due diligence with the intent to finalize a material definitive agreement outlining terms and conditions. Plandai expects its independent two-year audit to be finalized very soon and will form the basis for its operations going forward. 

For More on PLPL Subscribe Right Now!

Currently trading at a $6.6 million market valuation PLPL OS is 7,343,911,205 with 5,176,257,801 shares in the float. PLPL is a clean shell with just $420k in total liabilities and no note payables or convertible debt on the books. Back in 2014 a year when penny stocks and cannabis stocks especially made spectacular moves, PLPL was among the biggest runners of them all spiking up to over $3 per share at the time. A lot has happened since then including whipping $20 million in debt off the books via massive dilution over the years. PLPL today represents an exciting opportunity in small caps; the Company has just closed on 100% stock of EV Hotel Corp., with the official announcement coming next Tuesday. Plandai also plans to file with the SEC, Finra and OTC Markets Group for both a formal name and symbol change to reflect the new direction and identity of the Company. The “smart hotel,” EV Hotel™ operates a franchise model and it’s first franchisee is obtaining permits and converting a 63-year-old 114 room Travelodge into Phoenix, Arizona’s first ever smart hotel. According to this article “There are 11 locations planned for EV Hotel around the world, with the first set to open in Phoenix by the end of 2022 or early 2023, Patel said in a previous interview with Asian Hospitality. The rest are planned in California, Florida and elsewhere, with corporate headquarters in Atlanta. Mr. Patel said at closing: “I came to set the ultimate goal to revolutionize the hospitality industry like never before. Now one item is checked off and many more to achieve.” PLPL is quickly attracting a growing shareholder base that swears this one goes way higher. Microcapdaily will be covering PLPL / EV Hotel™ as it happens so make sure you subscribe to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in PLPL either long or short and we have not been compensated for this article.

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.